Lamin B1 is a novel therapeutic target of betulinic acid in pancreatic cancer

Clinical Cancer Research

Volumn 19, Issue 17, 2013, Pages 4651-4661

  Li, Lei ^a   Du, Yiqi ^a   Kong, Xiangyu ^a,c   Li, Zhaoshen ^a   Jia, Zhiliang ^c   Cui, Jiujie ^b,c   Gao, Jun ^a   Wang, Guokun ^a   Xie, Keping ^c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETULIC ACID; LAMIN; LAMIN B1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CARCINOGENICITY; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LAMIN TYPE B; MICE; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; TRITERPENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883480839     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3630     Document Type: Article

References (38)

1. Jemal A, Center MM, Ward E, Thun MJ. Cancer occurrence. Methods Mol Biol 2009;471:3-29.
2. Kindler HL. Pancreatic cancer: an update. Curr Oncol Rep 2007;9:170-6. (Pubitemid 46736349)
3. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004;91:586-94. (Pubitemid 38624667)
4. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36.
5. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 1996;223:273-9. (Pubitemid 26086718)
6. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997;225:621-33; discussion 633-6.
7. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical bene fit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13. (Pubitemid 27251144)
8. Gao Y, Jia Z, Kong X, Li Q, Chang DZ, Wei D, et al. Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Cancer Res 2011;71:5182-93.
9. Chintharlapalli S, Papineni S, Liu S, Jutooru I, Chadalapaka G, Cho SD, et al. 2-cyano-lup-1-en-3-oxo-20-oic acid, a cyano derivative of betulinic acid, activates peroxisome proliferator-activated receptor gamma in colon and pancreatic cancer cells. Carcinogenesis 2007;28:2337-46. (Pubitemid 350111592)
10. Liu X, Jutooru I, Lei P, Kim K, Lee SO, Brents LK, et al. Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer. Mol Cancer Ther 2012;11:1421-31.
11. Wan Y, Wu YL, Lian LH, Xie WX, Li X, Ouyang BQ, et al. The anti-fibrotic effect of betulinic acid is mediated through the inhibition of NF-kappaB nuclear protein translocation. Chem Biol Interact 2012;195:215-23.
12. Shin J, Lee HJ, Jung DB, Jung JH, Lee EO, Lee SG, et al. Suppression of STAT3 and HIF-1 alpha mediates anti-angiogenic activity of betulinic acid in hypoxic PC-3 prostate cancer cells. PLoS One 2011;6:e21492.
13. Chintharlapalli S, Papineni S, Ramaiah SK, Safe S. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res 2007;67:2816-23. (Pubitemid 46548971)
14. Yuan P, Wang L, Wei D, Zhang J, Jia Z, Li Q, et al. Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer. Cancer 2007;110:2682-90. (Pubitemid 350250337)
15. Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL, Xie K. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 2004;64:2030-8. (Pubitemid 38339450)
16. Dittmer TA, Misteli T. The lamin protein family. Genome Biol 2011;12:222.
17. Dauer WT, Worman HJ. New messages in the nuclear envelope. Cell Cycle 2010;9:645-6.
18. Dauer WT, Worman HJ. The nuclear envelope as a signaling node in development and disease. Dev Cell 2009;17:626-38.
19. Worman HJ, Fong LG, Muchir A, Young SG. Laminopathies and the long strange trip from basic cell biology to therapy. J Clin Invest 2009;119:1825-36.
20. Broers JL, Raymond Y, Rot MK, Kuijpers H, Wagenaar SS, Ramaekers FC. Nuclear A-type lamins are differentially expressed in human lung cancer subtypes. Am J Pathol 1993;143:211-20. (Pubitemid 24058175)
21. Moss SF, Krivosheyev V, de Souza A, Chin K, Gaetz HP, Chaudhary N, et al. Decreased and aberrant nuclear lamin expression in gastrointestinal tract neoplasms. Gut 1999;45:723-9. (Pubitemid 29492146)
22. Coradeghini R, Barboro P, Rubagotti A, Boccardo F, Parodi S, Carmignani G, et al. Differential expression of nuclear lamins in normal and cancerous prostate tissues. Oncol Rep 2006;15:609-13.
23. Lim SO, Park SJ, Kim W, Park SG, Kim HJ, Kim YI, et al. Proteome analysis of hepatocellular carcinoma. Biochem Biophys Res Commun 2002;291:1031-7. (Pubitemid 34694379)
24. Sun S, Xu MZ, Poon RT, Day PJ, Luk JM. Circulating Lamin B1 (LMNB1) biomarker detects early stages of liver cancer in patients. J Proteome Res 2010;9:70-8.
25. Harborth J, Elbashir SM, Bechert K, Tuschl T, Weber K. Identification of essential genes in cultured mammalian cells using small interfering RNAs. J Cell Sci 2001;114:4557-65. (Pubitemid 34086890)
26. Broers JL, Ramaekers FC, Bonne G, Yaou RB, Hutchison CJ. Nuclear lamins: laminopathies and their role in premature ageing. Physiol Rev 2006;86:967-1008. (Pubitemid 44042881)
27. Yang SH, Chang SY, Yin L, Tu Y, Hu Y, Yoshinaga Y, et al. An absence of both lamin B1 and lamin B2 in keratinocytes has no effect on cell proliferation or the development of skin and hair. Hum Mol Genet 2011;20:3537-44.
28. Kim Y, Sharov AA, McDole K, Cheng M,Hao H, FanCM, et al. Mouse B-type lamins are required for proper organogenesis but not by embryonic stem cells. Science 2011;334:1706-10.
29. Foster CR, Przyborski SA, Wilson RG, Hutchison CJ. Lamins as cancer biomarkers. Biochem Soc Trans 2010;38:297-300.
30. Maeno H, Sugimoto K, Nakajima N. Genomic structure of the mouse gene (Lmnb1) encoding nuclear lamin B1. Genomics 1995;30:342-6.
31. Lin F, Worman HJ. Expression of nuclear lamins in human tissues and cancer cell lines and transcription from the promoters of the lamin A/C and B1 genes. Exp Cell Res 1997;236:378-84. (Pubitemid 27505589)
32. Shi Q, Le X, Abbruzzese JL, Peng Z, Qian CN, Tang H, et al. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 2001;61:4143-54. (Pubitemid 32720983)
33. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8. (Pubitemid 32494397)
34. Lin F, Worman HJ. Structural organization of the human gene (LMNB1) encoding nuclear lamin B1. Genomics 1995;27:230-6.
35. Jung GR, Kim KJ, Choi CH, Lee TB, Han SI, Han HK, et al. Effect of betulinic acid on anticancer drug-resistant colon cancer cells. Basic Clin Pharmacol Toxicol 2007;101:277-85. (Pubitemid 350194804)
36. Pisha E, Chai H, Lee IS, Chagwedera TE, Farnsworth NR, Cordell GA, et al. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med 1995;1:1046-51.
37. Marin M, Karis A, Visser P, Grosveld F, Philipsen S. Transcription factor Sp1 is essential for early embryonic development but dispensable for cell growth and differentiation. Cell 1997;89:619-28. (Pubitemid 27511772)
38. Jackson DB. Serum-based microRNAs: are we blinded by potential? Proc Natl Acad Sci U S A 2009;106:E5.